

1 **Characteristics and outcomes of hospitalized adult COVID-19 patients in Georgia**

2 Tengiz Tsertsvadze, MD, PhD,<sup>1,2</sup> Marina Ezugbaia, MD,<sup>1</sup> Marina Endeladze, MD,<sup>1</sup> Levani  
3 Ratiani MD, PhD,<sup>3</sup> Neli Javakhishvili MD,<sup>4</sup> Lika Mumladze MD,<sup>5</sup> Manana Khotchava MD,  
4 PhD,<sup>6</sup> Maiko Janashia MD,<sup>7</sup> Diana Zviadadze MD,<sup>8</sup> Levan Gopodze MD,<sup>9</sup> Alex Gokhelashvili  
5 MD,<sup>10</sup> Revaz Metchurchtlishvili, MD,<sup>1</sup> Akaki Abutidze, MD, MPH, PhD,<sup>1,2</sup> Nikoloz  
6 Chkhartishvili, MD, MS, PhD<sup>1,11</sup>

7

8 <sup>1</sup>Infectious Diseases, AIDS and Clinical Immunology Research Center, Tbilisi, Georgia

9 <sup>2</sup>Ivane Javakhishvili Tbilisi State University, Tbilisi, Georgia

10 <sup>3</sup>First University Clinic, Tbilisi, Georgia

11 <sup>4</sup>Giorgi Abramishvili Military Hospital, Gori, Georgia

12 <sup>5</sup>St. King Mirian and Queen Nana Mtskheta Regional Medical Center, Georgia

13 <sup>6</sup>Children's Infectious Diseases Hospital, Tbilisi, Georgia

14 <sup>7</sup>University Clinic Rukhi, Georgia

15 <sup>8</sup>LJ Clinic Kutaisi, Georgia

16 <sup>9</sup>Central Republican Hospital, Tbilisi, Georgia

17 <sup>10</sup>Medalpha Clinic, Batumi, Georgia

18 <sup>11</sup>Caucasus International University, Tbilisi, Georgia

19

20 Corresponding author: Tengiz Tsertsvadze, MD, PhD

21 16 Akzbegi Avenue, Tbilisi 0160, Georgia

22 Telephone: (995 32) 23999922, Fax: (995 32) 2399144

23 Email: [tt@aidscenter.ge](mailto:tt@aidscenter.ge)

24 **Abstract**

25 **Objective:** Describe presenting characteristics of hospitalized patients and explore factors  
26 associated with in-hospital mortality during the first wave of pandemic in Georgia.

27 **Methods:** This retrospective study included 582 adult patients admitted to 9 dedicated COVID-  
28 19 hospitals as of July 30, 2020 (72% of all hospitalizations). Data were abstracted from medical  
29 charts. Factors associated with mortality were evaluated in multivariable Poisson regression  
30 analysis.

31 **Results:** Among 582 adults included in this analysis 14.9% were 65+ years old, 49.1% were  
32 women, 59.3% had uni- or bi-lateral lung involvement on chest computed tomography, 27.1%  
33 had any co-morbidity, 13.2% patients had lymphopenia, 4.1% had neutrophilosis, 4.8% had low  
34 platelet count, 37.6% had d-dimer levels of >0.5 mcg/l. Overall mortality was 2.1% (12/582).  
35 After excluding mild infections, mortality among patients with moderate-to-critical disease was  
36 3.0% (12/399), while among patients with severe-to-critical disease mortality was 12.7% (8/63).  
37 Baseline characteristics associated with increased risk of mortality in multivariate regression  
38 analysis included: age  $\geq 65$  years (RR: 10.38, 95% CI: 1.30-82.75), presence of any chronic co-  
39 morbidity (RR: 20.71, 95% CI: 1.58-270.99), lymphopenia (RR: 4.76, 95% CI: 1.52-14.93),  
40 neutrophilosis (RR: 7.22, 95% CI: 1.27-41.12), low platelet count (RR: 6.92, 95% CI: 1.18-  
41 40.54), elevated d-dimer (RR: 4.45, 95% CI: 1.48-13.35), elevated AST (RR: 6.33, 95% CI:  
42 1.18-33.98).

43 **Conclusion:** In-hospital mortality during the first wave of pandemic in Georgia was low. We  
44 identified several risk factors (older age, co-morbidities and laboratory abnormalities) associated  
45 with poor outcome that should provide guidance for planning health sector response as pandemic  
46 continues to evolve.

47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65  
66  
67  
68  
69

## **Introduction**

Ongoing pandemic of novel coronavirus disease 2019 (COVID-19) showed differential impact on mortality across the European continent, with cumulative mortality ranging from 1 to over 100 death per 100,000 population (1). Georgia is a small Eastern European country that rapidly responded to the pandemic threat by implementing effective public health and clinical measures achieving one of the lowest mortality rates of 1.25 per 100,000 population as of October 5, 2020 (1). The care pathway model included testing with real-time reverse transcriptase polymerase chain reaction (RT-PCR) of suspected cases (contacts of confirmed cases, persons with symptoms suggestive of COVID-19) with rapid hospitalization of all confirmed cases regardless of disease severity. Sixteen “fever” centres have been established for initial triage and RT-PCR diagnostics of symptomatic persons, while in-patient care was provided in 12 dedicated COVID-19 hospitals. The objective of this study was to describe presenting characteristics of hospitalized patients and explore factors associated with in-hospital mortality during the first wave of pandemic.

70 **Methods**

71

72 This retrospective study included unselected consecutive patients with RT-PCR confirmed  
73 COVID-19 admitted to 9 designated COVID-19 hospitals across the country between February  
74 26 and July 30, 2020, for whom complete outcome data was known (discharged alive or died in  
75 hospital).

76

77 As of July 30, 2020, 1160 persons with confirmed COVID-19 have been hospitalized in Georgia,  
78 among them outcome was available for 952 patients of whom 935 (98.2%) were discharged alive  
79 and 17 (1.8%) died. For present analysis complete outcome was available for 678 hospitalized  
80 persons (582 adults and 96 children) of whom 666 (98.2%) were discharged alive and 12 (1.8%)  
81 died. All lethal outcomes were registered among adults and therefore analysis was limited to  
82 persons aged  $\geq 18$  years.

83

84 Data were extracted from medical charts, including demographic characteristics, symptoms at  
85 presentation, vital signs, laboratory assays, presence of chronic co-morbid conditions,  
86 complications during hospital stay, admission to intensive care unit (ICU), need for oxygen  
87 support, treatment strategy and outcome of hospitalization. Treatment is provided in accordance  
88 with the national protocols, which is the “living guideline” regularly updated with emerging  
89 evidence. Confirmed cases were classified into mild, moderate, severe and critical disease.

90

91

92

93 **Results**

94

95 Among 582 adults included in this analysis the median age was 46 (IQR: 34-58) years, 14.9%  
96 were 65+ years old, 49.1% were women. At the time of hospitalization 13.1% patients had no  
97 symptoms, 59.3% had uni- or bi-lateral lung involvement on chest CT and 27.1% patients had  
98 any chronic co-morbid condition (cardiovascular disease, diabetes, cancer, chronic obstructive  
99 pulmonary disease, chronic kidney disease, chronic liver disease). With regard to baseline  
100 laboratory values 13.2% patients had lymphopenia, 4.1% had neutrophilosis, 4.8%  
101 thrombocytopenia, 37.6% had d-dimer levels of >0.5 mcg/l, 14.8% patients had AST levels >40  
102 IU/l and 14.3% had creatinine levels of >100 mcmol/l. Based on baseline characteristics 183  
103 (31.4%) patients were classified as having mild disease, 336 (57.7%) – moderate disease, 53  
104 (9.1%) – severe disease and 10 (1.7%) –critical disease.

105

106 Over the median length of stay of 20 (IQR: 16-24) days 12 adult died with mortality of 2.1%.  
107 Baseline characteristics associated with increased risk of mortality in multivariate regression  
108 analysis included: age  $\geq 65$  years (RR: 10.38, 95% CI: 1.30-82.75), presence of any chronic co-  
109 morbidity (RR: 20.71, 95% CI: 1.58-270.99), lymphocyte count  $< 1 \times 10^9/l$  (RR: 4.76, 95% CI:  
110 1.52-14.93), neutrophil count  $> 8 \times 10^9/l$  (RR: 7.22, 95% CI: 1.27-41.12), platelet count  $< 150 \times$   
111  $10^9/l$  (RR: 6.92, 95% CI: 1.18-40.54), d-dimer  $> 0.5$  mcg/ml (RR: 4.45, 95% CI: 1.48-13.35),  
112 AST  $> 40$  IU/l (RR: 6.33, 95% CI: 1.18-33.98) (Table 1).

113

114 Mortality rates by severity of disease at presentation were: 0.0% (0/183) for mild disease, 1.2%  
115 (4/336) for moderate, 3.8% (2/53) for severe disease and 60% (6/10) for critical disease (Table

116 2). After excluding mild infections, mortality among patients with moderate-to-critical disease  
117 was 3.0% (12/399), while among patients with severe-to-critical disease mortality was 12.7%  
118 (8/63).

119  
120 A total of 91 (15.6%) patients developed complications during hospital stay, including 25 (4.3%)  
121 patients developing multiple complications resulting in 11 deaths. Spectrum of complications  
122 included 43 (7.4%) new episodes of pneumonia, 19 (3.3%) acute respiratory distress syndrome, 6  
123 (1.0%) cardiovascular events (3 acute coronary disease, 2 ischemic strokes, 1 haemorrhagic  
124 stroke), 19 (3.3%) sepsis/septic shock, 6 (1.0%) acute liver injury, 10 (1.7%) acute kidney injury,  
125 19 (3.3%) cytokine storm (Table 2). Forty-one (7.0%) patients required admission to ICU  
126 resulting in 12 deaths (29.3% mortality) and 44 (7.6%) patients required oxygen support  
127 resulting in 12 deaths (27.3% mortality) (Table 2).

128  
129 Overall 282 (48.5%) patient received standard of care treatment only, 291 (50.0%) received  
130 hydroxychloroquine and 9 (4.8%) - lopinavir/ritonavir. In addition, 338 (58.1%) patients  
131 received antibiotics, 52 (8.9%) – corticosteroids, 2 (0.3%) - tocilizumab, 3 (0.5%) –  
132 plasmapheresis, 3 (0.5%) blood purification with cytosrobents and 2 (0.3%) transfusion of  
133 convalescent plasma.

134

135

136

137

138

139 **Discussion**

140

141 In this cohort of consecutive hospitalized adult patients with laboratory confirmed COVID-19 we  
142 found low in-hospital mortality of 2.1% among total population, 3% - among patients with at  
143 least moderate disease and 12.7% among patient with at least severe disease at presentation.

144 Overall mortality shown in our study is lower than 18.88% reported in recent meta-analysis, even  
145 if we limit our analysis to patients with severe/critical disease (2). However, the difference needs  
146 to be interpreted with caution in light of varying criteria for hospitalization and rationing of  
147 resources in overburdened healthcare systems (3). Reported rates of mortality among patients  
148 admitted to ICU or requiring ventilation ranges between 23% and 53% (4-7), with our study  
149 showing mortality of 29.3%.

150

151 Similar to other studies older age, presence of chronic comorbidities and laboratory  
152 abnormalities (leukopenia, neutrophilosis, thromocytopeia and increase in d-dimer) have been  
153 significantly associated with mortality (8-11). Interestingly, our data did not show gender-based  
154 differences neither in univariate nor multivariate analysis., while reports from other countries  
155 universally indicate increased risk of death among men (12).

156

157 Predicting outcomes of COVID\_19 disease has been a subject of intensive research (13). This is  
158 particularly important for Georgia as the country moved from hospitalize all approach to  
159 outpatient care of persons with mild disease because of significant increase in diagnosis since  
160 September 2020 (1). Defining criteria for hospitalization is crucial for appropriate utilization of  
161 healthcare resources without compromising lives. In our study baseline clinical characteristics,

162 such as fever, abnormalities in respiratory rate, oxygen saturation and chest CT imaging showed  
163 significant association with mortality only in univariate analysis. As an example, 4 patients in  
164 our cohort, initially classified to have moderate disease, had significant deterioration of their  
165 condition leading to death. All these 4 patients had pre-existing cardiovascular disease, 3 had  
166 elevated d-dimer along with lymphopenia – combination of factors that had been shown to  
167 predict progression of disease (14). This suggests that initial clinical presentation may not be  
168 sufficient for predicting outcome, it is rather complex issue that requires combinations of several  
169 determinants, including laboratory parameters.

170  
171 Our analysis included 72% of COVID-19 hospitalizations occurring in Georgia during the first  
172 wave of pandemic thus ensuring representativeness of national data. Limitations include small  
173 sample size and small number of events that affected statistical power. Analysis was limited to  
174 laboratory parameters included in basic package of care, while other biomarkers known to be  
175 associated with outcome such as albumin, IL-6, ferritin (15), were available only for small subset  
176 of patients.

177  
178 In summary, in-hospital mortality during the first wave of pandemic in Georgia was low. Our  
179 study characterized risk factors (older age, co-morbidities and laboratory abnormalities)  
180 associated with poor outcome that should provide guidance for planning health sector response  
181 as pandemic continues to evolve.

182

183

184



185 **References**

186

187 1. European Centre for Disease Prevention and Control. Situation dashboard - COVID-19  
188 cases in Europe and worldwide. Stockholm: ECDC; 2020 [cited 2020 October 5]; Available  
189 from: <https://qap.ecdc.europa.eu/public/extensions/COVID-19/COVID-19.html>.

190 2. Noor FM, Islam MM. Prevalence and Associated Risk Factors of Mortality Among  
191 COVID-19 Patients: A Meta-Analysis. *J Community Health*. 2020.

192 3. Emanuel EJ, Persad G, Upshur R, Thome B, Parker M, Glickman A, et al. Fair Allocation  
193 of Scarce Medical Resources in the Time of Covid-19. *N Engl J Med*. 2020 May  
194 21;382(21):2049-55.

195 4. Argenziano MG, Bruce SL, Slater CL, Tiao JR, Baldwin MR, Barr RG, et al.  
196 Characterization and clinical course of 1000 patients with coronavirus disease 2019 in New  
197 York: retrospective case series. *BMJ*. 2020:m1996.

198 5. Docherty AB, Harrison EM, Green CA, Hardwick HE, Pius R, Norman L, et al. Features  
199 of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical  
200 Characterisation Protocol: prospective observational cohort study. *BMJ*. 2020:m1985.

201 6. Grasselli G, Zangrillo A, Zanella A, Antonelli M, Cabrini L, Castelli A, et al. Baseline  
202 Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of  
203 the Lombardy Region, Italy. *Jama*. 2020 Apr 28;323(16):1574-81.

204 7. Karagiannidis C, Mostert C, Hentschker C, Voshaar T, Malzahn J, Schillinger G, et al.  
205 Case characteristics, resource use, and outcomes of 10 021 patients with COVID-19 admitted to  
206 920 German hospitals: an observational study. *Lancet Resp Med*. 2020;8(9):853-62.

- 207 8. Bonanad C, García-Blas S, Tarazona-Santabalbina F, Sanchis J, Bertomeu-González V,  
208 Fácila L, et al. The Effect of Age on Mortality in Patients With COVID-19: A Meta-Analysis  
209 With 611,583 Subjects. *J Am Med Dir Assoc*. 2020;21(7):915-8.
- 210 9. Harrison SL, Fazio-Eynullayeva E, Lane DA, Underhill P, Lip GYH. Comorbidities  
211 associated with mortality in 31,461 adults with COVID-19 in the United States: A federated  
212 electronic medical record analysis. *PLoS Med*. 2020 Sep;17(9):e1003321.
- 213 10. Martins-Filho PR, Tavares CSS, Santos VS. Factors associated with mortality in patients  
214 with COVID-19. A quantitative evidence synthesis of clinical and laboratory data. *European*  
215 *Journal of Internal Medicine*. 2020;76:97-9.
- 216 11. Zhang L, Yan X, Fan Q, Liu H, Liu X, Liu Z, et al. D-dimer levels on admission to  
217 predict in-hospital mortality in patients with Covid-19. *J Thromb Haemost*. 2020;18(6):1324-  
218 9.
- 219 12. Haitao T, Vermunt JV, Abeykoon J, Ghamrawi R, Gunaratne M, Jayachandran M, et al.  
220 COVID-19 and Sex Differences: Mechanisms and Biomarkers. *Mayo Clin Proc*. 2020  
221 Oct;95(10):2189-203.
- 222 13. Gupta RK, Marks M, Samuels THA, Luintel A, Rampling T, Chowdhury H, et al.  
223 Systematic evaluation and external validation of 22 prognostic models among hospitalised adults  
224 with COVID-19: An observational cohort study. *Eur Respir J*. 2020 Sep 25.
- 225 14. Feng Z, Yu Q, Yao S, Luo L, Zhou W, Mao X, et al. Early prediction of disease  
226 progression in COVID-19 pneumonia patients with chest CT and clinical characteristics. *Nature*  
227 *Communications*. 2020;11(1).
- 228 15. Henry BM, de Oliveira MHS, Benoit S, Plebani M, Lippi G. Hematologic, biochemical  
229 and immune biomarker abnormalities associated with severe illness and mortality in coronavirus

230 disease 2019 (COVID-19): a meta-analysis. Clinical Chemistry and Laboratory Medicine

231 (CCLM). 2020;58(7):1021-8.

232

233

234

235

236

237

238

239

240

241

242

243

244

245

246

247

248

249

250

251

252

**Table 1. Baseline characteristic of study population and factors associated with mortality (n=582)**

	Total, n (%)	Died, n (%)	Univariate analysis		Multivariate analysis	
			RR (95% CI)	p value	RR (95% CI)	p value
<b>Age categories</b>						
18-65	495 (85.1)	2 (0.4)	1		1	
65+	87 (14.9)	10 (11.5)	28.45 (6.34-127.63)	<0.0001	10.38 (1.30-82.75)	0.03
<b>Gender</b>						
Female	286 (49.1)	7 (2.4)	1		1	
Male	296 (50.9)	5 (1.7)	0.69 (0.22-2.15)	0.52	1.82 (0.47-7.08)	0.38
<b>Symptoms other than fever</b>						
Asymptomatic	76 (13.1)	1 (1.3)	1		1	
Symptomatic	506 (97.8)	11 (2.2)	1.65 (0.21-12.62)	0.63	0.17 (0.01-4.23)	0.28
<b>Temperature</b>						
<37	252 (43.3)	4 (1.6)	1		1	
37-<38	271 (46.6)	4 (1.5)	0.93 (0.24-3.68)	0.92	0.27 (0.06-1.16)	0.08
38+	59 (10.1)	4 (6.8)	4.27 (1.10-16.59)	0.04	0.25 (0.06-1.17)	0.08
<b>Respiratory rate</b>						
<24	520 (89.3)	4 (0.8)	1		1	
24+	62 (10.7)	8 (12.9)	16.78 (5.20-54.10)	<0.0001	1.90 (0.25-14.58)	0.53
<b>Oxygen saturation</b>						
≥94	530 (91.1)	6 (1.1)	1		1	
<94	52 (8.9)	6 (11.5)	10.19 (3.41-30.47)	<0.0001	1.69 (0.37-7.75)	0.50
<b>Chest CT</b>						
No lung involvement	237 (40.7)	1 (0.4)	1		1	
Uni- or Bi-lateral involvement	345 (59.3)	11 (3.19)	7.56 (0.98-58.14)	0.05	1.51 (0.09-24.62)	0.77
<b>Comorbidities</b>						
No comorbidities	424 (72.9)	1 (0.2)	1		1	
Any comorbidity	158 (27.1)	11 (7.0)	29.52 (3.84-226.78)	0.001	21.15 (1.60-280.56)	0.02

<b>BMI</b>						
<25	238 (40.9)	5 (2.1)	1		1	
25-30	283 (48.6)	4 (1.4)	0.67 (0.18-2.48)	0.55	0.19 (0.02-1.48)	0.11
>30	61 (10.5)	3 (4.9)	2.34 (0.58-9.53)	0.23	1.50 (0.29-7.88)	0.63
<b>Hemoglobin</b>						
≥12 g/dl	521 (89.5)	8 (1.5)	1		1	
<12 g/dl	61 (10.5)	4 (6.6)	4.27 (1.32-13.77)	0.02	1.67 (0.54-5.14)	0.37
<b>White blood count</b>						
≤11 X 10 <sup>9</sup> /l	564 (96.9)	9 (1.6)	1		1	
>11 X 10 <sup>9</sup> /l	18 (3.1)	3 (16.7)	10.44 (3.09-35.36)	0.002	3.29 (0.31-35.26)	0.33
<b>Lymphocyte count</b>						
≥1 X 10 <sup>9</sup> /l	505 (86.8)	6 (1.2)	1		1	
<1 X 10 <sup>9</sup> /l	77 (13.2)	6 (7.8)	6.56 (2.17-19.82)	0.0009	4.74 (1.48-15.10)	0.008
<b>Neutrophil count</b>						
≤8 X 10 <sup>9</sup> /l	558 (95.9)	9 (1.6)	1		1	
>8 X 10 <sup>9</sup> /l	24 (4.1)	3 (12.5)	7.75 (2.24-26.81)	0.001	7.27 (1.26-41.89)	0.03
<b>Platelet count</b>						
≥150 X 10 <sup>9</sup> /l	553 (95.2)	10 (1.8)	1		1	
<150 X 10 <sup>9</sup> /l	28 (4.8)	2 (7.1)	3.94 (0.91-17.18)	0.07	6.99 (1.20-40.61)	0.03
<b>D-dimer</b>						
≤0.5 mcg/ml	363 (62.4)	2 (0.6)	1		1	
>0.5 mcg/ml	219 (37.6)	10 (4.6)	8.29 (1.83-37.48)	0.006	4.47 (1.51-13.24)	0.007
<b>C reactive protein</b>						
≤5 mg/l	214 (36.8)	2 (0.9)	1		1	
>5 mg/l	368 (63.2)	10 (2.7)	2.91 (0.64-13.15)	0.17	1.26 (0.17-9.51)	0.82
<b>ALT</b>						
≤40 IU/l	468 (80.4)	9 (1.9)	1		1	
>40 IU/l	114 (19.6)	3 (2.6)	1.37 (0.38-4.97)	0.63	4.54 (0.77-26.93)	0.10

<b>AST</b>						
≤40 IU/l	496 (85.2)	7 (1.4)	1		1	
>40 IU/l	86 (14.8)	5 (5.8)	4.12 (1.34-12.68)	0.01	6.34 (1.18-34.13)	0.03
<b>Creatinine</b>						
≤100 μmol/l	499 (85.7)	8 (1.6)	1		1	
>100 μmol/l	83 (14.3)	4 (4.8)	3.01 (0.93-9.76)	0.07	1.88 (0.56-6.31)	0.31

255 **Table 2. Mortality by severity of disease and complications during hospital stay (n=582)**

	<b>Total (n=582)</b>	<b>Discharged alive (n=570)</b>	<b>Died (n=12)</b>	<b>p value</b>
<b>Severity of disease at baseline, n (%)</b>				
Mild	183 (31.4)	183 (100.0)	0 (0.0)	0.0007
Moderate	336 (57.7)	332 (98.8)	4 (1.2)	
Severe	53 (9.1)	51 (96.2)	2 (3.8)	
Critical	10 (1.7)	4 (40.0)	6 (60.0)	
<b>Complications during hospital stay, n (%)</b>				
None	491 (84.4)	491 (100.0)	0 (0.0)	<0.0001
1 complication	66 (11.3)	65 (98.5)	1 (1.5)	
>1 complication	25 (4.3)	14 (56.0)	11 (44.0)	
<b>Pneumonia, n (%)</b>				
No	539 (92.6)	528 (98.0)	11 (2.0)	0.61
Yes	43 (7.4)	42 (97.7)	1 (2.3)	
<b>ARDS, n (%)</b>				
No	554 (95.2)	552 (99.6)	2 (0.4)	<0.0001
Yes	28 (4.8)	18 (64.3)	10 (35.7)	
<b>Cardiovascular events, n (%)</b>				
None	576 (99.0)	568 (98.6)	8 (1.4)	<0.0001
Acute coronary disease	3 (0.5)	0 (0.0)	3 (100.0)	
Ischemic stroke	2 (0.3)	2 (100.0)	0 (0.0)	
Hemorrhagic stroke	1 (0.2)	0 (0.0)	1 (100.0)	
<b>Sepsis/septic shock, n (%)</b>				
No	563 (96.7)	562 (99.8)	1 (0.2)	<0.0001
Yes	19 (3.3)	8 (42.1)	11 (57.9)	
<b>Acute liver injury, n (%)</b>				
No	576 (99.0)	565 (98.1)	11 (1.9)	0.11
Yes	6 (1.0)	5 (83.3)	1 (16.7)	
<b>Acute kidney injury, n (%)</b>				
No	572 (98.3)	565 (98.8)	1 (1.2)	<0.0001
Yes	10 (1.7)	5 (50.0)	1 (50.0)	
<b>Cytokine storm, n (%)</b>				
No	563 (96.7)	554 (98.4)	9 (1.6)	0.005
Yes	19 (3.3)	16 (84.2)	3 (15.8)	
<b>Admission to ICU, n (%)</b>				
No	541 (93.0)	541 (100.0)	0 (0.0)	<0.0001
Yes	41 (7.0)	29 (70.7)	12 (29.3)	
<b>Oxygen support, n (%)</b>				
No oxygen support	538 (92.4)	538 (100.0)	0 (0.0)	<0.0001
Oxygen support, n (%)	44 (7.6)	32 (72.7)	12 (27.3)	

